ZZZhaolei Zou

Zhaolei Zou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhaolei Zou has a total of 52 co-authors. Here are the top co-authors by number of shared publications:

  • Juan Fang

    Hospital of Stomatology, Guanghua School of Stomatology, Guangdong Provincial Key Laboratory of Stomatology, Sun Yat-sen University, Guangzhou, 510055, China

    4 shared publications
  • Zhi Wang

    Hospital of Stomatology, Guanghua School of Stomatology, Guangdong Provincial Key Laboratory of Stomatology, Sun Yat-Sen University, Guangzhou, China

    3 shared publications
  • Jingyi Lu

    Hospital of Stomatology, Guanghua School of Stomatology, Guangdong Provincial Key Laboratory of Stomatology, Sun Yat-sen University, Guangzhou, 510055, China

    2 shared publications
  • Qiannan Hu

    Hospital of Stomatology, Guanghua School of Stomatology, Guangdong Provincial Key Laboratory of Stomatology, Sun Yat-sen University, Guangzhou, 510055, China

    2 shared publications
  • Shuqiong Wen

    Guanghua School of Stomatology, Guangdong Provincial Key Laboratory of Stomatology, Stomatological Hospital, Sun Yat-sen University, Guangzhou 510055, China

    2 shared publications
  • Zhi Wang

    Hospital of Stomatology, Guanghua School of Stomatology, Guangdong Provincial Key Laboratory of Stomatology, Sun Yat-Sen University, 56 Lingyuan Road West, Guangzhou, 510055, Guangdong, China

    2 shared publications

Latest Publications

  • Ketogenic Fasting Suppresses Tumor Growth and Enhances PD-1 Blockade Efficacy Through Glutamine Partitioning and Microbial Metabolite Remodeling

    by Min Xiao, Arabella H. Wan, Run Lin, Heteng Zhang, Nan You, Heng Liang, Chuwei Liu, Yuyan Zheng, Shijia Yan, Zitong Zhang, et al.

    Many tumors remain poorly responsive to immune checkpoint blockade. The metabolic microenvironment in tumors can mediate immunosuppression by failing to sustain productive cytotoxic lymphocyte function. Here, we showed that a coordinated ketogenic-fasting (KF) regimen sensitized immune-refractory tumors to PD-1 blockade by integrating distinct metabolic and microbial effects of ketogenic diet (KD) and intermittent fasting (IF). The KF combination established a distinct immunometabolic state that could not be fully recapitulated by either KD or IF intervention alone. KF induced systemic glucose restriction while preserving intratumoral glutamine availability and selectively upregulating the glutamine transporters SLC38A1 and SLC38A2 in tumor-infiltrating CD8+ T cells and NK cells, fueling interferon-STAT1 signaling and effector activity. Single-cell transcriptomic analysis identified KF-associated cytotoxic lymphocyte states characterized by enhanced nutrient access signatures, increased effector function, and reduced terminal dysfunction. Microbiota depletion attenuated KF-mediated tumor control without abolishing intratumoral glutamine enrichment. Fecal microbiota transfer and monocolonization identified Odoribacter splanchnicus as sufficient to restore tumor control and cytotoxic T-cell activity in microbiota-depleted hosts. Mechanistically, O. splanchnicus was linked to host polyamine remodeling and indole-3-lactic acid, which supported durable CD8+ T-cell functions distinct from the glutamine-driven effector arm. KF enhanced anti-PD-1 efficacy in immune-cold tumor models, and public human datasets showed concordant associations between glutamine context, Odoribacter abundance, and immunotherapy response. Together, these findings identify a diet-responsive host–microbiota metabolic mechanism that stimulates antitumor immunity and sensitizes immune-cold tumors to immunotherapy.

  • Open Access

    Sharp nanothorn-equipped ionogel microrobots for targeted periodontitis therapy

    by Dongqing He, Zhaolei Zou, Dongdong Jin, Zichang Guo, Yinuo Song, Qiannan Hu, Muqiao Yu, Jingyi Lu, Juan Fang, Qianqian Wang, et al.

    Periodontitis necessitates targeted therapy due to its high prevalence, progressive tissue destruction, and systemic disease links. Conventional mechanical debridement and pharmacological treatments are limited by complex periodontal barriers, including viscous crevicular fluid and resilient biofilms, which impede bacterial eradication and drug delivery. Here, we engineered magnetically actuated microrobots with gold nanothorns for disrupting biofilms and penetrating mucus barriers. Fabricated by encapsulating curcumin in antibacterial ionogel microspheres with asymmetric magnetic deposition and nanothorn functionalization, these microrobots enabled precise magnetic navigation in viscous media, while penetrating a biomimetic mucus analog, enhancing periodontal retention, and mechanically dislodging biofilms. Furthermore, ethanol-responsive release of curcumin enhanced its bioavailability, thereby scavenging free radicals and modulating macrophage phenotypes to alleviate inflammation. Guided by a toothbrushing-inspired handheld magnetic controller, microrobots evaluated using in vivo murine models demonstrated reduced inflammation, inhibited bone resorption, improved tissue health, and oral microbiota remodeling toward ecological balance, showing promise for targeted periodontitis therapy.

  • Open Access

    Comprehensive analysis of clinical research profiles and study characteristics of oral potentially malignant disorders: an observational study

    by Lijian Zhao, Yuqing Qu, Yanshu Zhang, Zhaolei Zou, Jingyi Lu, Zhi Wang, Bin Li, Juan Fang

  • Open Access

    Regulation of autoimmune disease progression by Pik3ip1 through metabolic reprogramming in T cells and therapeutic implications

    by Wenqiang Xie, Juan Fang, Zhongyan Shan, Junyi Guo, Yuan Liao, Zhaolei Zou, Jun Wang, Shuqiong Wen, Lisa Yang, Yanshu Zhang, et al.

    Metabolic alterations could profoundly affect immune functions and influence the progression and outcome of autoimmune diseases. However, the detailed mechanisms and their therapeutic potential remain to be defined. Here, we show that phosphatidylinositide 3-kinase interacting protein 1 (Pik3ip1), a newly identified negative immune regulator, is notably down-regulated in several major autoimmune diseases through a previously unidentified mechanism mediated by interleukin-21/p38 mitogen-activated protein kinase/a disintegrin and metalloprotease-17 (ADAM17) pathway. Down-regulation of Pik3ip1 in T cells causes a major metabolic shift from oxidative phosphorylation toward aerobic glycolysis, leading to their overactivation and aggressive disease progression in experimental autoimmune encephalomyelitis (EAE) mouse model. Suppression of hypoxia-inducible factor 1α (Hif1α) or pharmacologic inhibition of glycolysis could reverse these phenotypes and largely mitigate EAE severity. Our study reveals a previously unrecognized role of Pik3ip1 in metabolic regulation that substantially affects the inflammatory loop in the autoimmune setting and identifies the Pik3ip1/Hif1α/glycolysis axis as a potential therapeutic target for treatment of autoimmune diseases.


  • Open Access

    The Current Landscape of Oral Squamous Cell Carcinoma: A Comprehensive Analysis from ClinicalTrials.gov

    by Zhaolei Zou, Bin Li, Shuqiong Wen, Dongjia Lin, Qiannan Hu, Zhi Wang, Juan Fang

    Objective: A better understanding of the current characteristics of clinical trials in oral squamous cell carcinoma (OSCC) is important to improve trial design and identify neglected areas of research. The objective is to summarize the current characteristics and publication status of OSCC trials registered on ClinicalTrials.gov. Methods: The ClinicalTrials.gov database was searched on November 9, 2020, for trials containing the term “oral squamous cell carcinoma”. We assessed the characteristics of the included trials and searched the publication status of the primary completed trials by using PubMed and Google Scholar. Results: Our search identified 325 studies for analysis, including 279 interventional (85.8%) and 46 observational (14.2%) studies. Interventional studies were mostly single-group (50.9%), single-center (57.0%), non-randomized (59.1%), open-label (81.4%), and early-phase (70.6%) trials. The vast majority of the studies (82.8%) focused on the treatment of OSCC. Chemotherapy (36.8%) was the most common treatment, followed by targeted therapy (15.2%) and immunotherapy (15.2%). Furthermore, 58.9% of the primary completed interventional studies were published by January 8, 2021, and the median time to publication was 48.0 months. Studies registered before this study began (HR = 1.69, 95% CI = 1.02–2.80, P = .040) and in phases 1/2 or 2 (HR = 2.10, 95% CI = 1.09–4.06, P = .026) were associated with an improved likelihood of publication. Conclusions: OSCC clinical trials usually have small sample size and are open-label and non-randomized studies. Advanced OSCC and immunotherapy-oriented therapy are becoming the focus of current trials. Researchers should perform standardized registration and publish their results in a timely manner.